Century Therapeutics (IPSC) Operating Margin (2022 - 2025)
Historic Operating Margin for Century Therapeutics (IPSC) over the last 4 years, with Q1 2025 value amounting to 67.95%.
- Century Therapeutics' Operating Margin rose 37298200.0% to 67.95% in Q1 2025 from the same period last year, while for Sep 2025 it was 29.91%, marking a year-over-year increase of 53561300.0%. This contributed to the annual value of 2096.48% for FY2024, which is 44603900.0% up from last year.
- As of Q1 2025, Century Therapeutics' Operating Margin stood at 67.95%, which was up 37298200.0% from 893.46% recorded in Q4 2024.
- Over the past 5 years, Century Therapeutics' Operating Margin peaked at 67.95% during Q1 2025, and registered a low of 35431.31% during Q2 2023.
- Its 4-year average for Operating Margin is 8053.42%, with a median of 3661.87% in 2024.
- As far as peak fluctuations go, Century Therapeutics' Operating Margin crashed by -331855400bps in 2023, and later soared by 309235300bps in 2024.
- Century Therapeutics' Operating Margin (Quarter) stood at 6392.71% in 2022, then tumbled by -155bps to 16329.1% in 2023, then soared by 95bps to 893.46% in 2024, then skyrocketed by 108bps to 67.95% in 2025.
- Its Operating Margin stands at 67.95% for Q1 2025, versus 893.46% for Q4 2024 and 4398.1% for Q3 2024.